SAN
DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that the Company will participate in the following investor
conferences:
- Wells Fargo Healthcare Conference: Fireside chat on
Wednesday, September 4, 2024, at
2:15 p.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference:
Fireside chat on Monday, September 9,
2024, at 10:00 a.m. ET
The live events and replays of the presentations
will be available under "Events and Presentations" through the
investor relations section of the Company's website at
https://ir.regulusrx.com/events and archived for 90 days
following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq:
RGLS) is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs. Regulus
has leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with the Company's RGLS8429 program and preclinical
pipeline, the potential that RGLS8429 may be eligible for an
Accelerated Approval pathway, potentially achieving therapeutic
efficacy and clinical translation for patients, the expected
timing for reporting interim or topline data, and the timing and
future occurrence of other preclinical and clinical activities.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that the approach we are
taking to discover and develop drugs is novel and may never lead to
marketable products, that preliminary or topline results are based
on a preliminary analysis of key efficacy and safety data, and such
data may change following a more comprehensive review of the data
related to the clinical trial and may not be indicative of future
results, the FDA has not designated RGLS8429 for an Accelerated
Approval pathway and such designation may not lead to a faster
development, regulatory review or approval process and does not
increase the likelihood that RGLS8429 will receive marketing
approval, the risk that preclinical and clinical studies may not be
successful, risks related to regulatory review and approval, risks
related to our reliance on third-party collaborators and other
third parties, risks related to intellectual property, risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, the risk that additional toxicology data may be
negative, and risks related to our ability to successfully secure
and deploy capital. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission, including under the "Risk Factors" heading of
Regulus' quarterly report on Form 10-Q available on the Company's
website or at www.sec.gov. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Regulus undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-302232255.html
SOURCE Regulus Therapeutics Inc.